Enanta Pharmaceuticals
ENTA
144 hedge funds and large institutions have $805M invested in Enanta Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 43 increasing their positions, 64 reducing their positions, and 13 closing their positions.
836% more call options, than puts
Call options by funds: $4.12M | Put options by funds: $440K
2.83% more ownership
Funds ownership: 92.44% → 95.28% (+2.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
1% less funds holding
Funds holding: 146 → 144 (-2)
7% less capital invested
Capital invested by funds: $869M → $805M (-$63.9M)
33% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 64
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$34M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$9.45M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$9.32M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$8.64M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$14.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.91M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$5.25M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$5.12M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$4.96M |
ENTA Hedge Fund Activity: Q1 2023 in Review
144 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2023, worth a combined $805M — down 7.4% from $869M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ENTA and 12 opened new positions — a net loss of 1 holder — while 64 trimmed existing stakes and 43 added.
The largest buyer was Braidwell, adding an estimated $34M. The largest seller was State Street, cutting an estimated $14.9M.
- 144 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2023, down from 146 in Q4 2022.
- Funds reported $805M of Enanta Pharmaceuticals stock for Q1 2023, down 7.4% quarter-over-quarter.
- 12 funds opened new Enanta Pharmaceuticals positions in Q1 2023 and 13 closed out, a net change of -1 holder.
- The largest Enanta Pharmaceuticals buyer in Q1 2023 was Braidwell, an estimated $34M added.
- The largest Enanta Pharmaceuticals seller in Q1 2023 was State Street, an estimated $14.9M sold.
Based on aggregated 13F filings for Q1 2023.